Home Cart 0 Sign in  

[ CAS No. 120-14-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 120-14-9
Chemical Structure| 120-14-9
Structure of 120-14-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 120-14-9 ]

Related Doc. of [ 120-14-9 ]

Alternatived Products of [ 120-14-9 ]

Product Details of [ 120-14-9 ]

CAS No. :120-14-9 MDL No. :MFCD00003363
Formula : C9H10O3 Boiling Point : -
Linear Structure Formula :- InChI Key :WJUFSDZVCOTFON-UHFFFAOYSA-N
M.W :166.17 Pubchem ID :8419
Synonyms :
Veratraldehyde

Calculated chemistry of [ 120-14-9 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.81
TPSA : 35.53 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.45 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.83
Log Po/w (XLOGP3) : 1.22
Log Po/w (WLOGP) : 1.52
Log Po/w (MLOGP) : 0.83
Log Po/w (SILICOS-IT) : 1.98
Consensus Log Po/w : 1.47

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.81
Solubility : 2.57 mg/ml ; 0.0155 mol/l
Class : Very soluble
Log S (Ali) : -1.56
Solubility : 4.54 mg/ml ; 0.0273 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.59
Solubility : 0.424 mg/ml ; 0.00255 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.3

Safety of [ 120-14-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 120-14-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 120-14-9 ]
  • Downstream synthetic route of [ 120-14-9 ]

[ 120-14-9 ] Synthesis Path-Upstream   1~52

  • 1
  • [ 120-14-9 ]
  • [ 14430-23-0 ]
Reference: [1] Tetrahedron Letters, 1994, vol. 35, # 30, p. 5413 - 5416
  • 2
  • [ 120-14-9 ]
  • [ 21560-29-2 ]
Reference: [1] Tetrahedron, 1982, vol. 38, # 22, p. 3347 - 3354
  • 3
  • [ 120-14-9 ]
  • [ 4790-08-3 ]
Reference: [1] Molecules, 2006, vol. 11, # 12, p. 968 - 977
  • 4
  • [ 120-14-9 ]
  • [ 16382-18-6 ]
Reference: [1] Archives of Pharmacal Research, 2011, vol. 34, # 3, p. 357 - 367
  • 5
  • [ 120-14-9 ]
  • [ 528-48-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 16, p. 7598 - 7616
  • 6
  • [ 120-14-9 ]
  • [ 855-97-0 ]
Reference: [1] Tetrahedron, 2004, vol. 60, # 11, p. 2647 - 2655
[2] European Journal of Medicinal Chemistry, 2014, vol. 86, p. 153 - 164
  • 7
  • [ 120-14-9 ]
  • [ 22608-87-3 ]
Reference: [1] Synthetic Communications, 2014, vol. 44, # 3, p. 346 - 351
[2] Tetrahedron Letters, 2015, vol. 56, # 25, p. 3954 - 3960
  • 8
  • [ 623-73-4 ]
  • [ 120-14-9 ]
  • [ 4687-37-0 ]
Reference: [1] Tetrahedron, 1998, vol. 54, # 43, p. 13237 - 13252
  • 9
  • [ 120-14-9 ]
  • [ 55-59-4 ]
Reference: [1] Canadian Journal of Chemistry, 1974, vol. 52, # 16, p. 2873 - 2879
[2] RSC Advances, 2017, vol. 7, # 7, p. 4203 - 4208
  • 10
  • [ 120-14-9 ]
  • [ 120-20-7 ]
Reference: [1] Organic Letters, 2006, vol. 8, # 8, p. 1525 - 1528
[2] Tetrahedron, 2002, vol. 58, # 8, p. 1471 - 1478
[3] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 1, p. 87 - 95
[4] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980, vol. 19, # 4, p. 272 - 275
[5] Indian Journal of Chemistry - Section B Organic Chemistry Including Medicinal Chemistry, 1989, vol. 28, # 5, p. 431 - 434
[6] Chemical and Pharmaceutical Bulletin, 1978, vol. 26, # 1, p. 155 - 160
[7] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 15, p. 4862 - 4871
[8] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 4, p. 856 - 868
[9] Journal of Medicinal Chemistry, 2013, vol. 56, # 23, p. 9673 - 9682
[10] Chemistry - An Asian Journal, 2015, vol. 10, # 4, p. 925 - 937
[11] Patent: CN105461627, 2016, A,
[12] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 6, p. 1437 - 1440
[13] RSC Advances, 2018, vol. 8, # 51, p. 28997 - 29007
[14] Patent: CN108358913, 2018, A,
  • 11
  • [ 120-14-9 ]
  • [ 13575-75-2 ]
Reference: [1] Journal of Organic Chemistry, 1985, vol. 50, # 24, p. 4933 - 4938
[2] Journal of Organic Chemistry, 2013, vol. 78, # 16, p. 7823 - 7844
  • 12
  • [ 120-14-9 ]
  • [ 5653-40-7 ]
Reference: [1] Molecules, 2018, vol. 23, # 1,
[2] RSC Advances, 2016, vol. 6, # 81, p. 77717 - 77734
  • 13
  • [ 120-14-9 ]
  • [ 13794-72-4 ]
Reference: [1] Synthetic Communications, 2014, vol. 44, # 3, p. 346 - 351
[2] Molecules, 2018, vol. 23, # 1,
  • 14
  • [ 120-14-9 ]
  • [ 7417-21-2 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 18, p. 8422 - 8440
  • 15
  • [ 120-14-9 ]
  • [ 776-99-8 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1989, vol. 25, # 7.2, p. 1332 - 1337[2] Zhurnal Organicheskoi Khimii, 1989, vol. 25, # 7, p. 1477 - 1482
[3] Chimica Therapeutica, 1968, vol. 3, p. 313 - 320
[4] Tetrahedron, 1975, vol. 31, p. 2595 - 2601
[5] Journal of Medicinal Chemistry, 1974, vol. 17, p. 427 - 430
  • 16
  • [ 93-15-2 ]
  • [ 776-99-8 ]
  • [ 120-14-9 ]
Reference: [1] Advanced Synthesis and Catalysis, 2010, vol. 352, # 9, p. 1533 - 1538
  • 17
  • [ 79-24-3 ]
  • [ 120-14-9 ]
  • [ 776-99-8 ]
Reference: [1] Russian Journal of Organic Chemistry, 1995, vol. 31, # 7, p. 927 - 933[2] Zhurnal Organicheskoi Khimii, 1995, vol. 31, # 7, p. 1002 - 1008
  • 18
  • [ 17639-93-9 ]
  • [ 120-14-9 ]
  • [ 776-99-8 ]
Reference: [1] Synthetic Communications, 1982, vol. 12, # 5, p. 355 - 360
  • 19
  • [ 120-14-9 ]
  • [ 124702-80-3 ]
Reference: [1] RSC Advances, 2015, vol. 5, # 34, p. 26596 - 26603
  • 20
  • [ 141-82-2 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
YieldReaction ConditionsOperation in experiment
96% With 1,4-diaza-bicyclo[2.2.2]octane In N,N-dimethyl-formamide at 100 - 110℃; for 1.25 h; General procedure: To aromatic aldehyde (500 mg, 1.0 equiv) and malonic acid (981 mg, 2.0 equiv) was added DABCO (105 mg, 2 equiv) in dimethyl formamide (5 mL) and the reaction mixture was stirred at 100-110 °C for 60-90 min. After completion of the reaction (TLC monitoring), reaction mixture was poured in water and then extracted with ethyl acetate. Crude product was recrystallized from chloroform/hexane system to provide cinnamic acids in good yield.
88%
Stage #1: at 105 - 110℃;
Stage #2: With sodium hydroxide In water at 25 - 30℃;
Stage #3: With sulfuric acid In water at 15 - 20℃;
To a solution of 1000 g (6.024 mol) of 3, 4-dimethoxybenzaldehyde in 3L pyridine, 1378.3 g (13.25 mol) of malonic acid and 100 mL of piperidine were added. The resulting mixture was stirred at 105 °C to 1 10 °C for 6 - 8 h. After completion of the reaction, the reaction mixture was cooled to 25 °C to 30 °C and slowly quenched the reaction mixture into 10 L of 5 percent sodium hydroxide solution at 25 °C to 30 °C (pH: 9- 10). The reaction mixture was washed with ethyl acetate (2 x 5 L) and the organic layer separated was washed with 2 L of 5 percent sodium hydroxide solution. The aqueous layers were combined and cooled to 15 °C to 20 °C. The aqueous layer was acidified slowly with 2.5 L of 50 percent sulphuric acid below 20 °C (pH: 1-2). After an additional 30 - 45 min stirring at 15 °C to 20 °C, the solid obtained was collected by filtration, washed with 10 L of water followed by 4 L of n-hexane. The partially dried compound was unloaded into trays and dried at 55 °C to 60 °C for 8-10 h to give 1 1 10 g of the title compound.Yield: 1 1 10 g (88 percent); 1H NMR (DMSO-d6, 300 MHz): δ 7.51 (d, 1 H), 7.30 (s, 1 H), 7.19 (d, 1 H), 6.96 (d, 1 H), 6.44 (d, 1 H), 3.79 (s, 6H); MS (ES-): 207 (M-1 ).
88.9% at 75℃; for 5 h; 100 g of a three-necked reaction flask was charged with 25 g (240 mmol)Malonic acid, 33.2 g (200 mmol)3,4-dimethoxybenzaldehyde,40 ml (496 mmol) of pyridine,2 ml (20.4 mmol) of hexahydropyridine,Heated to 75 ° C and then reflux 5h,Reaction is completed,Cooling 10min,150 ml of 3 mol / ml of ice hydrochloric acid solution was added,Place the night,Filter,The precipitate was washed with 1000 ml of water,Get white crude.The crude product was recrystallized from absolute ethanol,A mixture of 37.0 g of pure white 3,4-dimethoxyphenylacrylic acid,Yield 88.9percent.
86.5% at 85℃; for 4 h; 1. In a 100 ml three-necked flask, 6.24 g (60 mmol) of malonic acid, 8.3g (50 mmol) of 3,4-dimethoxybenzaldehyde, 10 ml (124 mmol) of pyridine and 0.5 ml (5.1 mmol) of piperidine were heated 85°C for 4h. After completion of the reaction, the solution was cooled for 10 min, 60 ml of 3 mol / ml ice hydrochloric acid solution was added, and the mixture was left to stand overnight. The precipitate was washed with 400 ml of water to give a white crude product. The crude product was recrystallized from absolute ethanol to give 9 g of white pure 3,4-dimethoxyphenylacrylic acid in a yield of 86.5percent.
71.4% for 4 h; Reflux Example 7
Preparation of 3,4-Dimethoxycinnamic acid
In a 1L round bottomed flask fitted with a magnetic stirrer and a reflux condenser, a mixture of 166 g (1 mol) of veratraldehyde and 208 g (2 mol) of malonic acid in 500 mL of pyridine and 5 mL of piperidine was refluxed for 4 h. The excess pyridine was evaporated using a rotavap and 3 L of water was added to the syrupy residue which caused the formation of a solid. The mixture was acidified with 250 mL of concentrated HCl with stirring. Filtration and washing with three 100-mL portions of water and drying in air afforded 150 g (71.4percent) of the cinnamic acid, m.p. 183-185 °C. (lit. m.p. 180-182 °C.) as shown in J. G. Stuart et al, /. Het. Chem., 24. 1589 (1987); 1H-NMR (DMSO-d6) δ 3.78 (s, 3), 3.80 (s, 3), 6.44 (d, 1), 6.96 (d, 1) 7.19 (dd, 1), 7.31 (d,l), 7.52 (d, 1).

Reference: [1] Organic Letters, 2016, vol. 18, # 5, p. 1182 - 1185
[2] Oriental Journal of Chemistry, 2012, vol. 28, # 4, p. 1725 - 1728
[3] Asian Journal of Chemistry, 2017, vol. 29, # 7, p. 1561 - 1564
[4] Journal of Heterocyclic Chemistry, 1987, vol. 24, # 6, p. 1589 - 1594
[5] RSC Advances, 2015, vol. 5, # 34, p. 26596 - 26603
[6] Patent: WO2011/104680, 2011, A1, . Location in patent: Page/Page column 60
[7] Patent: CN106187969, 2016, A, . Location in patent: Paragraph 0079; 0080
[8] Patent: CN105541773, 2016, A, . Location in patent: Paragraph 0041
[9] Beilstein Journal of Organic Chemistry, 2009, vol. 5,
[10] Synthetic Communications, 2000, vol. 30, # 20, p. 3769 - 3774
[11] Journal of Medicinal Chemistry, 2001, vol. 44, # 26, p. 4716 - 4732
[12] European Journal of Organic Chemistry, 2018, vol. 2018, # 8, p. 1041 - 1052
[13] Patent: WO2015/9837, 2015, A1, . Location in patent: Page/Page column 13; 24
[14] Green Chemistry, 2009, vol. 11, # 4, p. 526 - 530
[15] Journal of the Chemical Society, 1928, p. 1661
[16] Archiv der Pharmazie (Weinheim, Germany), 1928, p. 119
[17] Journal of the Chemical Society, 1925, vol. 127, p. 1720
[18] Journal of the Chemical Society, 1925, vol. 127, p. 1977
[19] Journal of the Indian Chemical Society, 1927, vol. 4, p. 406[20] Chem. Zentralbl., 1928, vol. 99, # I, p. 1048
[21] Bulletin de la Societe Chimique de France, 1962, p. 496 - 502
[22] Journal of Organic Chemistry, 1963, vol. 28, # 11, p. 2937 - 2943
[23] Phytochemistry (Elsevier), 1984, vol. 23, # 6, p. 1313 - 1316
[24] Patent: WO2007/10085, 2007, A2, . Location in patent: Page/Page column 17-18
[25] Molecules, 2009, vol. 14, # 10, p. 4166 - 4179
[26] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 17, p. 6351 - 6359
[27] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 1, p. 53 - 56
[28] Synlett, 2012, vol. 23, # 5, p. 760 - 764
[29] Journal of Molecular Catalysis B: Enzymatic, 2012, vol. 82, p. 92 - 95
[30] Molecules, 2014, vol. 19, # 10, p. 16058 - 16081
[31] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 19, p. 6389 - 6403
[32] Chemistry - A European Journal, 2017, vol. 23, # 3, p. 554 - 557
[33] RSC Advances, 2017, vol. 7, # 55, p. 34448 - 34460
[34] Molecules, 2018, vol. 23, # 9,
  • 21
  • [ 141-82-2 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
  • [ 58818-70-5 ]
Reference: [1] Journal of the Chemical Society, 1928, p. 1661
[2] Tetrahedron Letters, 2013, vol. 54, # 39, p. 5370 - 5373
  • 22
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
Reference: [1] Tetrahedron, 1982, vol. 38, # 22, p. 3347 - 3354
[2] Synthetic Communications, 2009, vol. 39, # 18, p. 3254 - 3262
[3] Journal of the Indian Chemical Society, 2013, vol. 90, # 10, p. 1853 - 1860
  • 23
  • [ 4887-24-5 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6183 - 6196
  • 24
  • [ 108-24-7 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
Reference: [1] Journal of the Chemical Society, 1904, vol. 85, p. 162
[2] Chemische Berichte, 1909, vol. 42, p. 1984[3] Chem. Zentralbl., 1910, vol. 81, # I, p. 1621
  • 25
  • [ 120-14-9 ]
  • [ 141-78-6 ]
  • [ 2316-26-9 ]
Reference: [1] Recueil des Travaux Chimiques des Pays-Bas, 1926, vol. 45, p. 358[2] Recueil des Travaux Chimiques des Pays-Bas, 1928, vol. 47, p. 734
  • 26
  • [ 110-89-4 ]
  • [ 110-86-1 ]
  • [ 141-82-2 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
Reference: [1] Journal of the Chemical Society, 1925, vol. 127, p. 1720
  • 27
  • [ 141-82-2 ]
  • [ 7664-41-7 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
  • [ 58818-70-5 ]
Reference: [1] Journal of the Chemical Society, 1928, p. 1661
  • 28
  • [ 127-09-3 ]
  • [ 108-24-7 ]
  • [ 120-14-9 ]
  • [ 2316-26-9 ]
Reference: [1] Journal of the Chemical Society, 1904, vol. 85, p. 162
  • 29
  • [ 120-14-9 ]
  • [ 1016-58-6 ]
Reference: [1] Chemical Communications, 2017, vol. 53, # 68, p. 9470 - 9473
  • 30
  • [ 120-14-9 ]
  • [ 21852-32-4 ]
Reference: [1] Journal of Organic Chemistry, 1994, vol. 59, # 20, p. 5999 - 6007
[2] Journal of the Indian Chemical Society, 1989, vol. 66, # 8-10, p. 656 - 659
[3] Chemical Biology and Drug Design, 2011, vol. 78, # 1, p. 101 - 111
[4] European Journal of Medicinal Chemistry, 2012, vol. 55, p. 125 - 136
[5] Journal of Steroid Biochemistry and Molecular Biology, 2013, vol. 137, p. 332 - 344
[6] Organic Letters, 2014, vol. 16, # 2, p. 484 - 487
[7] European Journal of Medicinal Chemistry, 2014, vol. 86, p. 740 - 751
[8] Synlett, 2016, vol. 27, # 9, p. 1391 - 1396
[9] Patent: CN107540636, 2018, A,
[10] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 12, p. 2131 - 2135
[11] MedChemComm, 2018, vol. 9, # 11, p. 1862 - 1870
  • 31
  • [ 120-14-9 ]
  • [ 5417-17-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1986, vol. 29, # 9, p. 1586 - 1590
  • 32
  • [ 120-14-9 ]
  • [ 6635-20-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4367 - 4371
  • 33
  • [ 120-14-9 ]
  • [ 10535-17-8 ]
Reference: [1] Green Chemistry, 2018, vol. 20, # 16, p. 3761 - 3771
  • 34
  • [ 120-14-9 ]
  • [ 5392-10-9 ]
YieldReaction ConditionsOperation in experiment
98% With bromine In methanol; water at 20℃; for 4 h; (1)
To a solution of 500g of 3,4-dimethoxybenzaldehyde in 2.5L of methanol was added dropwise 529g of bromine at room temperature (under cooled condition, if necessary) over 1 hour, and the mixture was stirred at the same temperature for 3 hours.
To the reaction solution was added dropwise 2.5L of water, and the crystals were precipitated.
To a suspension of the crystal was added 20percent aqueous sodium hydroxide solution at room temperature to adjust it to pH about 9 to 10, and then cooled.
The precipitated crystals were collected by filtration and washed with water, and then dried at 50°C for 12 hours to give 718.78g of 6-bromo-3,4-dimethoxybenzaldehyde (yield: 98percent).
95% With bromine In methanol at 20℃; for 3 h; Bromine (1.82 mL, 5.67 g, 31.5 mmol) was added dropwise to a stirred solution of veratraldehyde (4.98 g, 30.0 mmol) in MeOH (25 mL) in 7 minutes to bring the solution to gentle reflux. After 3 hours the reaction mixture color changed to pale orange and some solid precipitated. The reaction mixture was diluted with MeOH for the precipitate dissolution and it was poured into water (120 mL). To the yellow suspension was added 20percent NaOH solution until pH = 10. The precipitate was filtered, washed with water and dissolved in CH2Cl2 (120 mL). The organic solution was washed with brine, dried over Na2SO4 and concentrated in vacuo to give pure by 1H NMR bromobenzaldehyde SI-1b (6.99 g, 28.5 mmol, 95percent) as white solid. Recrystallization from EtOAc/hexane (1/2)gives 6.32 g (25.8 mmol, 86percent) of crystalline product in two crops if needed.
89% With bromine In methanol at 15 - 40℃; for 24 h; 3,4-Dimethoxybenzaldehyde (100 g, 0.602 mol) represented by the following Formula 1 was dissolved in 600 mL of methanol, Control solution temperature is 15 ~ 20 deg C, Bromine (106 g, 0.663 mol) was added dropwise thereto, After the addition was complete, the solution was warmed to 35-40 ° C, Reaction for 24 hours. Continue to add 10percent aqueous sodium thiosulfate solution (200 ml, 0.126 mol)Steamed out 200 ml of methanol, The solution is then cooled to 10-15 ° C, Stirred for 2 hours, Suction filtration, Dried to give the following formula 2 130 grams of light yellow solid 3,4-bismethoxy-2-bromobenzaldehyde, Yield 89percent.
86% With bromine In methanol at 20℃; for 6 h; [0067] Total Synthesis of Patentifiorin A (3) (Scheme 1 ) . To a solution of veratral (4a) (63.2 mmo.) in methanol (MeOH, 250 mL), a solution of bromine (Br2, 69.5 mmol) was added slowly. The reaction was allowed to stir at room temperature for 6 hr to afford 2- bromo-veratral (13.4 g, 86 percent). 2-Bromo-veratra. (50.3 mmol) was then dissolved in 300 mL benzene, to which, 1 , 3-propanedifhiol (50.4 mmol) and p-toluenesulfonic acid (p- TsOH, 2.5 mmol) were added. The reaction mixture was allowed to be stirred at reflux for 10 hr then ambient temperature for 48 hr to yield 5 (15.6 g, 93 percent). To a stirred solution of compound 5 (46.6 mmoi) in tetrahydrofuran (THF, 1 50 mL) at -78 °C was added n-butyllithium (n-BuLi) (1 .6 M solution in hexanes, 69.9 mmol) in 1 hr, followed by addition of a solution of piperonal (4b) (55.9 mmol) in THF (30 mL). The reaction was allowed for a further 2 hr and then 3 hr at room temperature to yield 6 (9.5 g, 50 percent). Compound 6 (20.7 mmol) in CH2CI2 (200 mL) was added a suspension of activated manganese dioxide (MnO2, 345 mmol) at room temperature. The reaction was allowed for 16 hr, and was then filtered through a plug of celite to afford the oxidative product 7 (8.2 g, 98 percent). n-Butyliithium (1 .6M solution in hexanes, 100 mmoi) was added dropwise over 5 min to a cooled (-78 °C) solution of diisopropylamine (100 mmoi) in THF (43 mL) under Argon to make fresh lithium diisopropylamide (LDA) solution. The solution was warmed to ambient temperature over 30 min and 25.7 mL added, dropwise via syringe over 3 min to a cooled (-78 °C) THF solution (80 mL) of the dithiane 7 (14.29 mmoi). After 40 min, 2,5-dihydrofuranone (17.1 mmol) as a solution in THF (10 mL) was added over 1 min. The reaction is warmed to ambient temperature for 1 hr to afford 8 (3.95 g, 57 percent). A solution of compound 8 (0.85 mmol), mercury oxide (HgO, 0.71 mmoi) and mercury chloride (HgC , 1 .43 mmol) in 84 percent acetonitriie (AcCN) aqueous (25 mL) was heated to reflux for 3 hr to afford 9 (134 mg, 52 percent). The ketone 9 (0.34 mmol) and p~ TsOH (0.19 mmol) were heated to reflux in benzene (150 mL) for 18 hr to yield the desired compound diphyllin (10, 108 mg, 83 percent). To the solution of D-quinovose (0.61 mmol) in pyridine (5 mL) was added 4-dimethylaminopyridine (DMAP, 0.06 mmol) and acetic anhydride (AC2O, 1 .5 mL) at room temperature, and the mixture was stirred overnight and quenched with MeOH (1 mL) to afford 1 ,2,3,4-tetraacetyl-D-quinovose. Without further separation, the tetraacetate was dissolved in glacial acetic acid (AcOH, 1 mL), and 1 .5 mL hydrobromic acid (HBr) (33percent in AcOH) was added to the solution slowly at room temperature. The reaction was allowed for 15 min to afford 11 (215 mg, 97 percent). To a solution of TBAB (tetrabutylammonium bromide, 0.95 mmoi) and diphyllin (10, 0.95 mmol) in 15 mL of dichloromethane (CH2C ) was added aqueous 0.1 M sodium hydroxide (NaOH, 20 mL). After stirring for 10 min at 40 °C, compound 11 (0.81 mmol) was then added, and the two-phase reaction was stirred for 6 hr at 40 °C to afford the solid 12. Without further separation, the solid 12 (538 mg) was dissolved in MeOH (10 mL), and potassium carbonate (K2CO3, 1 .0 mmol) was then added. The reaction was allowed for 1 hr to afford patentiflorin A (3) (122 mg).
85.85% at 20℃; for 3.5 h; I. Synthesis of 2-Bromo-4,5-dimethoxybenzaldehyde of formula VI; Three necked round bottom flask (500 mL) equipped with dropping funnel, magnetic stirrer, and stopper was charged with veratraldehyde or 4,5-dimethoxybenzaldehyde (formula V, 15 g, 0.090 mole) and acetic acid (210 mL). To this solution was added bromine (9.67 mL) in acetic acid (60 mL) dropwise with constant stirring over half an hour and stirring was further continued for 3 h at room temperature. During this time all the starting materials was consumed as confirmed by TLC (3:7, EtOAc:Hexane). Water (250 mL) was added to the reaction mixture and cooled to 0° C. The precipitated solid was filtered off, washed with cold water and dried under vacuum to get a white solid 2-bromo-4,5-dimethoxybenzaldehyde (formula VI).The yield and NMR details of compound of compound of formula VI were as follows:Yield: 19 g (85.85percent)1HNMR (CDCl3, 300 MHz): δ=10.19 (s, 1H), 7.43 (s, 1H), 7.07 (s, 1H), 3.97 (s, 3H), 3.93 (s, 3H).
81.3% With bromine In methanol at 25 - 40℃; for 3 h; Example 1
Preparation of 2-Bromo-4,5-dimethoxybenzaldehyde
In a 5 liter (L) 3-neck round bottomed flask fitted with a mechanical stirrer, a dropping funnel and a thermometer, there was added 500 grams (g) (3001 millimoles (mmol)) of veratraldehyde in 1500 milliliter (mL) of methanol. Due to the endothermic solution process the temperature of the solution dropped below 25°C and therefore the solution was warmed with a heating mantle until the temperature again reached 25 °C. At this point 573.5 g (3589 mmol, 185 mL) of bromine was added dropwise at such a rate that the temperature remained under 40°C to avoid the formation of the 2,3-dibromo derivative. The addition required about one hour and gave a reddish yellow solution. After about two hours a precipitate began to separate and after three hours, 7 L of water was added and the precipitate was filtered and washed with an additional 7 L of water. Recrystallization from 7 L of ethanol gave 600 g (81.3percent) of the bromo aldehyde, melting point (m. p.) 145-146°C (lit. m.p. 149-151°C, as shown in S. Chandrasekhar et al. Tetrahedron 62, 12908 (2006)); IR (NaCl): 1683, 1594, 1504 cm"1; 1H-NMR (CDC13) δ 3.88 (s, 3), 3.93 (s, 3), 7.02 (s, 1), 7.37 (s, 1), 10.14 (s, 1). 13C-NMR (CDC13, 75 MHz): δ 56.05, 56.44, 110.28, 115.34, 120.26, 126.41, 148.76, 154.37, 190.55.
76.1% With bromine In acetic acidInert atmosphere Prepared according to the literature [3], starting with veratraldehyde (49.85 g, 0.3 mol) in glacial acetic acid (400 mL), adding bromine (18.5 mL, 0.3 mol) in 100 mL glacial acetic acid, yielding 55.95 g (76.1percent) of 3c, colourless needles, mp 149-150°C (80percent MeOH). Chemical formula: C9H9BrO3. Molecular weight: 245.07. Elemental analysis: Calculated: C, 44.11; H, 3.70; found: C, 44.25; H, 3.79. 1H-NMR (400 MHz; CDCl3): 3.91 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 7.04 (s, 1H, C3-H), 7.40 (s, 1H, C6-H), 10.17 (s, 1H, CHO). 13C-{1H}-NMR (100 MHz; CDCl3): 56.1, 56.5, 110.4, 115.4, 120.4, 126.5, 148.9, 154.5, 190.8.
56% With bromine; sodium hydrogencarbonate; sodium thiosulfate In acetic acid First Stage
Synthesis of 6-bromo-3,4-dimethoxybenzaldehyde
A solution of bromine (0.96 g) in acetic acid (10 ml) was dropped into a solution of 3,4-dimethoxybenzaldehyde (1.0 g) in acetic acid (4 ml) and the mixture was stirred for three hours.
Sodium thiosulfate was added to the reaction mixture, then sodium bicarbonate was added thereto and the mixture was filtered.
The crude crystals collected by the filtration were recrystallized from chloroform-ether to give the title compound (0.83 g, 56percent).
The peaks of this compound in 1H-NMR (400 MHz, CDCl3) were as follows.

Reference: [1] Heterocycles, 2015, vol. 90, # 1, p. 730 - 739
[2] Patent: WO2007/40240, 2007, A1, . Location in patent: Page/Page column 26
[3] Advanced Synthesis and Catalysis, 2015, vol. 357, # 14-15, p. 3255 - 3261
[4] Patent: EP1964925, 2016, B1, . Location in patent: Paragraph 0068
[5] Journal of Asian Natural Products Research, 2012, vol. 14, # 4, p. 322 - 326
[6] Tetrahedron Letters, 2016, vol. 57, # 1, p. 11 - 14
[7] Chemistry - A European Journal, 2013, vol. 19, # 45, p. 15080 - 15083
[8] Chinese Chemical Letters, 2014, vol. 25, # 7, p. 1044 - 1046
[9] Journal of Organic Chemistry, 2018, vol. 83, # 2, p. 930 - 938
[10] Tetrahedron Letters, 1998, vol. 39, # 15, p. 2087 - 2088
[11] Journal of Organic Chemistry, 2015, vol. 80, # 22, p. 11605 - 11610
[12] Tetrahedron, 2006, vol. 62, # 51, p. 12098 - 12107
[13] Organic Process Research and Development, 1999, vol. 3, # 6, p. 425 - 431
[14] Acta Crystallographica Section C: Crystal Structure Communications, 1997, vol. 53, # 8, p. 1141 - 1143
[15] Organic Letters, 2005, vol. 7, # 13, p. 2723 - 2726
[16] Journal of Organic Chemistry, 2000, vol. 65, # 20, p. 6398 - 6411
[17] Patent: CN106749358, 2017, A, . Location in patent: Paragraph 0048; 0049; 0050; 0051
[18] Canadian Journal of Chemistry, 1996, vol. 74, # 1, p. 88 - 94
[19] Patent: WO2013/19662, 2013, A1, . Location in patent: Paragraph 0067
[20] Journal of Natural Products, 2017, vol. 80, # 6, p. 1798 - 1807
[21] Patent: US2012/29179, 2012, A1, . Location in patent: Page/Page column 6
[22] Journal of the Iranian Chemical Society, 2011, vol. 8, # 2, p. 531 - 536
[23] Patent: WO2015/9837, 2015, A1, . Location in patent: Page/Page column 12; 20
[24] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1990, # 11, p. 2929 - 2936
[25] Journal of Organic Chemistry, 1986, vol. 51, # 18, p. 3490 - 3493
[26] Journal of Organic Chemistry, 2006, vol. 71, # 17, p. 6682 - 6685
[27] Tetrahedron Letters, 1994, vol. 35, # 23, p. 3879 - 3882
[28] Journal of the American Chemical Society, 2008, vol. 130, # 48, p. 16417 - 16423
[29] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 3, p. 814 - 823
[30] Journal of the Chemical Society, Chemical Communications, 1991, # 14, p. 972 - 973
[31] Journal of Organic Chemistry, 2007, vol. 72, # 25, p. 9786 - 9789
[32] Tetrahedron, 1995, vol. 51, # 37, p. 10115 - 10124
[33] Journal of Chemical Research - Part S, 1996, # 7, p. 334 - 335
[34] Chemistry of Natural Compounds, 1993, vol. 29, # 6, p. 748 - 759[35] Khimiya Prirodnykh Soedinenii, 1993, # 6, p. 839 - 853
[36] Journal of Organic Chemistry, 2002, vol. 67, # 19, p. 6772 - 6787
[37] Synthetic Communications, 2009, vol. 39, # 3, p. 506 - 515
[38] Tetrahedron Letters, 2001, vol. 42, # 39, p. 6973 - 6975
[39] Patent: US6180659, 2001, B2,
[40] Journal of Materials Chemistry B, 2015, vol. 3, # 37, p. 7457 - 7465
[41] RSC Advances, 2018, vol. 8, # 32, p. 17806 - 17812
[42] Journal fuer Praktische Chemie (Leipzig), 1981, vol. 323, # 4, p. 673 - 676
[43] Justus Liebigs Annalen der Chemie, 1912, vol. 391, p. 44
[44] Chem. Zentralbl., 1905, vol. 76, # II, p. 623
[45] Journal of Organic Chemistry, 1990, vol. 55, # 5, p. 1471 - 1475
[46] Tetrahedron Letters, 1992, vol. 33, # 45, p. 6883 - 6884
[47] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1993, # 21, p. 2599 - 2604
[48] Tetrahedron Letters, 1998, vol. 39, # 37, p. 6757 - 6760
[49] Journal of Chemical Research, 2006, # 11, p. 698 - 701
[50] Chemistry - A European Journal, 2007, vol. 13, # 22, p. 6452 - 6460
[51] Patent: US2004/15015, 2004, A1, . Location in patent: Page 13
[52] Patent: WO2006/72818, 2006, A2, . Location in patent: Page/Page column 18
[53] Patent: US5969140, 1999, A,
[54] Journal of Chemical Research, 2009, # 7, p. 420 - 422
[55] Tetrahedron, 2012, vol. 68, # 6, p. 1745 - 1749
[56] Organic Letters, 2013, vol. 15, # 11, p. 2582 - 2585
[57] Mendeleev Communications, 2016, vol. 26, # 4, p. 285 - 287
[58] Patent: WO2018/193476, 2018, A2, . Location in patent: Page/Page column 47; 48
  • 35
  • [ 7726-95-6 ]
  • [ 120-14-9 ]
  • [ 64-19-7 ]
  • [ 5392-10-9 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1912, vol. 391, p. 44
[2] Chem. Zentralbl., 1905, vol. 76, # II, p. 623
  • 36
  • [ 120-14-9 ]
  • [ 1835-02-5 ]
Reference: [1] Chemistry Letters, 1979, p. 209 - 212
  • 37
  • [ 120-14-9 ]
  • [ 6451-86-1 ]
Reference: [1] Tetrahedron, 2006, vol. 62, # 51, p. 12098 - 12107
  • 38
  • [ 120-14-9 ]
  • [ 4998-07-6 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic Chemistry Including Medicinal Chemistry, 1989, vol. 28, # 5, p. 431 - 434
[2] Chemische Berichte, 1899, vol. 32, p. 3407
[3] Molecules, 2018, vol. 23, # 1,
[4] RSC Advances, 2016, vol. 6, # 81, p. 77717 - 77734
  • 39
  • [ 120-14-9 ]
  • [ 35202-54-1 ]
Reference: [1] Patent: US2014/107334, 2014, A1,
[2] Patent: US2014/163220, 2014, A1,
  • 40
  • [ 120-14-9 ]
  • [ 2450-26-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4367 - 4371
  • 41
  • [ 120-14-9 ]
  • [ 53413-67-5 ]
Reference: [1] Chemical Communications, 2017, vol. 53, # 68, p. 9470 - 9473
  • 42
  • [ 120-14-9 ]
  • [ 18066-68-7 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 1979, vol. 52, p. 2013 - 2022
  • 43
  • [ 120-14-9 ]
  • [ 555-30-6 ]
Reference: [1] Patent: CN105693541, 2016, A,
  • 44
  • [ 2024-83-1 ]
  • [ 52805-46-6 ]
  • [ 120-14-9 ]
Reference: [1] Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 4, p. 980 - 988
  • 45
  • [ 120-14-9 ]
  • [ 1953-04-4 ]
Reference: [1] Organic Process Research and Development, 1999, vol. 3, # 6, p. 425 - 431
  • 46
  • [ 120-14-9 ]
  • [ 122892-31-3 ]
Reference: [1] Patent: CN106748862, 2017, A,
  • 47
  • [ 120-14-9 ]
  • [ 123-54-6 ]
  • [ 160096-59-3 ]
YieldReaction ConditionsOperation in experiment
34%
Stage #1: With boric anhydride In ethyl acetate at 45℃; for 0.5 h;
Stage #2: With boric acid tributyl ester In ethyl acetate at 45℃; for 0.5 h;
Stage #3: With N-butylamine In ethyl acetate at 45℃; for 16 h;
2,4-Pentanedione (3 g, 30.0 mmol) and boric anhydride (1 .46g, 21 .Ommol) weredissolved in ethyl acetate (EA) (30 ml) and heated at 45 °C for 30 minutes. 3,4-Dimethoxybenzaldehyde (9.96 g, 59.9mmol) and tributylborate (13.79 g, 59.9 mmol)were added and the mixture stirred at 45 °C for 30 minutes. Butylamine (4.44 ml, 44.9mmol) in EA (30 ml) was added dropwise over 15 minutes and the solution stirred at 45°C for 16 hours. Aqueous HCI (prepared by adding 4.5 ml conc. HCI to 25.5 ml water)was added and the biphasic mixture stirred and heated at 60 °C for 1 hour. The layerswere separated and the aqueous layer extracted with EA (50 ml). The combinedorganic layers were washed with water, saturated NaCI, dried with Na2504, filtered and the solvents removed under reduced pressure to give crude product as a red oil (10.42g). The crude product was purified by FC on silica gel eluting with EA:hexane (50:50) togive (1 E,6E)-1 ,7-bis(3,4-dimethoxyphenyl)hepta-1 ,6-diene-3,5-dione as an orangesolid (4.0 g, 34percent). HPLC-UV showed >97percent purity. 1H NMR (60 MHz, ODd3), 16.05(1H, bs), 7.59 (2H, d), 6.76-7.26 (6H, m), 6.45 (2H, d), 5.79 (1H, s), 3.91 (6H, s), 3.89(6H, s).
2.8%
Stage #1: With boron trioxide In ethyl acetate at 85℃; for 0.666667 h;
Stage #2: With triethyl borate In ethyl acetate at 85℃; for 3 h;
To a solution of 2,4-pentadione (12 ml, 117 mmol) in AcOEt was added boron trioxide (4.17 g, 59.9 mmol) at room temperature. After stirring for 40 min at 85 oC, 3,4-dimethoxybenzaldehyde (9.64 g, 58.1 mmol) and triethyl borate (5.0 ml, 29.4 mmol) were added to the reaction mixture. After stirring for 3 h at same temperature, the mixture was added to the n-BuNH2 (2.0 ml, 8.30 mmol). After stirring for 1 h at same temperature, to the reaction mixture was added 1 M HCl at 50 oC and extracted with AcOEt. The organic phase was washed with brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (hexane/AcOEt, 4:1) to give 2 (112 mg, 2.8percent) as an orange powder. 1H NMR (400 MHz, CDCl3): 4.0 (s, 12H), 5.82 (s, 1H), 6.49 (d, 2H, J = 5.8 Hz), 6.88 (d, 2H, J = 8.4Hz), 7.07 (s, 1H), 7.16 (d, 2H, J = 8.4 Hz), 7.60 (d, 2H, J = 16 Hz). ESIHRMS m/z: C23H24O6 [M+H]+ calcd 397.1651, found 397.1608.
Reference: [1] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 1, p. 360 - 367
[2] Patent: WO2018/149578, 2018, A1, . Location in patent: Page/Page column 16; 17
[3] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 24, p. 5621 - 5626
[4] Journal of Mass Spectrometry, 1998, vol. 33, # 4, p. 319 - 327
[5] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 11, p. 3811 - 3820
[6] Journal of Medicinal Chemistry, 2010, vol. 53, # 23, p. 8260 - 8273
[7] Journal of Biological Chemistry, 2011, vol. 286, # 2, p. 1114 - 1124
  • 48
  • [ 120-14-9 ]
  • [ 111-30-8 ]
  • [ 160096-59-3 ]
YieldReaction ConditionsOperation in experiment
5.6 g With N-butylamine In N,N-dimethyl-formamide at 70℃; for 3 h; Inert atmosphere The dimethoxy curcumin bulk drug is prepared by reference to the full synthetic route provided by the U.S. Patent (US005679864A). The preparation process is briefly described below. Methyl vanillin (23.3 g), boron oxide (4.66 g), anhydrous dimethylformamide (90 mL), pentanedione (7.2 mL) and dimethoxypropane (17.2 mL) were sequentially placed in 250 mL three-necked bottle, well-stoppered, after shaking evenly, slowly heated up to 70 ° C under N2 protection, until the solid matter was completely dissolved, n-butylamine (2.8 mL) was slowly added dropwise, and the reaction was completed in about 120 min, and the reaction was continued for about 1 h, the reaction solution was poured into 400 mL of boiling 5percent acetic acid solution while stirring, and was homogeneously stirred untill naturally cooled to room temperature, 200 mL of deionized water was added, well shaked, let stand for 2 days in a refrigerator at 4 ° C and pour off the upper layer solution. Acetonitrile aqueous solution (~63percent) was added, the lower layer of the viscous solid was dissolved under reflux for 30 min, filtered while hot, and the filtrate was placed in a refrigerator at 4 ° C for crystallization. Filtered, the obtained solid was repeatedly washed with a 60percent aqueous solution of acetonitrile and dried to give orange yellow needle crystals (5.6 g).
Reference: [1] Patent: CN105012234, 2018, B, . Location in patent: Paragraph 0041-0042
  • 49
  • [ 120-14-9 ]
  • [ 123-54-6 ]
  • [ 93006-00-9 ]
  • [ 160096-59-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 2, p. 685 - 690
  • 50
  • [ 288-32-4 ]
  • [ 120-14-9 ]
  • [ 870837-62-0 ]
  • [ 870837-70-0 ]
Reference: [1] Journal of the American Chemical Society, 2017, vol. 139, # 45, p. 16100 - 16104
  • 51
  • [ 120-14-9 ]
  • [ 35202-55-2 ]
Reference: [1] Patent: US2014/163220, 2014, A1,
  • 52
  • [ 13078-21-2 ]
  • [ 120-14-9 ]
  • [ 94687-10-2 ]
Reference: [1] Green Chemistry, 2018, vol. 20, # 16, p. 3761 - 3771
[2] Journal of the American Chemical Society, 2013, vol. 135, # 17, p. 6415 - 6418
[3] Angewandte Chemie, International Edition, 2015, vol. 54, # 1, p. 258 - 262[4] Angewandte Chemie,
[5] Patent: WO2015/138563, 2015, A1, . Location in patent: Page/Page column 24
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 120-14-9 ]

Dacomitinib Related Intermediates

Chemical Structure| 179552-74-0

[ 179552-74-0 ]

N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine

Chemical Structure| 162012-67-1

[ 162012-67-1 ]

N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine

Chemical Structure| 446-32-2

[ 446-32-2 ]

2-Amino-4-fluorobenzoic acid

Chemical Structure| 179552-75-1

[ 179552-75-1 ]

N4-(3-Chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine

Chemical Structure| 3473-63-0

[ 3473-63-0 ]

Formamidine acetate

Similar Product of
[ 120-14-9 ]

Chemical Structure| 1173022-44-0

A1269570[ 1173022-44-0 ]

3,4-Dimethoxy[7-13C]-benzaldehyde

Reason: Stable Isotope

Related Functional Groups of
[ 120-14-9 ]

Aldehydes

Chemical Structure| 86-81-7

[ 86-81-7 ]

3,4,5-Trimethoxybenzaldehyde

Similarity: 0.97

Chemical Structure| 29865-90-5

[ 29865-90-5 ]

3-Hydroxy-4,5-dimethoxybenzaldehyde

Similarity: 0.97

Chemical Structure| 66855-92-3

[ 66855-92-3 ]

3-(2-Methoxyphenoxy)benzaldehyde

Similarity: 0.97

Chemical Structure| 3934-87-0

[ 3934-87-0 ]

3,4-Dihydroxy-5-methoxybenzaldehyde

Similarity: 0.97

Chemical Structure| 78725-48-1

[ 78725-48-1 ]

4-(2-Methoxyphenoxy)benzaldehyde

Similarity: 0.94